Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study

Liarakos, Alexandros L; Hasan, Nebras; Crabtree, Thomas S J; Leelarathna, Lalantha; Hammond, Peter; Hussain, Sufyan; Haq, Masud; Aslam, Aisha; Gatdula, Erneda; Gibb, Fraser W; Lumb, Alistair; Bull, Kirsty; Chinnasamy, Eswari; Carrieri, Giorgio; Williams, David M; Choudhary, Pratik; Ryder, Robert E J; Wilmot, Emma G

Abstract

Aims
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System

Methods
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service network. Hemoglobin A1c (HbA1c), sensor-derived glucometrics, total daily dose of insulin (TDD), and patient-reported outcome changes between baseline and follow-up were assessed. Individuals were classified to “new-to-pump” (switched from multiple daily injections) and “established-on-pump” (switched from a tethered insulin pump) groups.

Results
276 individuals from 11 centers [66.7 % female; 92 % White British; median age 41 years (IQR 20–50); diabetes duration 20 years (IQR 11–31); 49.3 % within “new-to-pump” group] were included. Baseline HbA1c was 8.0 ± 1.3 % (64 ± 14 mmol/mol). At follow-up [3 years (IQR 1.5–3.2)], HbA1c reduced by 0.3 % [(3 mmol/mol); p = 0.002] across the total population, 0.4 % [(5 mmol/mol); p = 0.001] in those “new-to-pump” and remained unchanged in those “established-on-pump”. TDD decreased in the “new-to-pump” cohort (baseline:44.9 ± 21.0units vs follow-up:38.1 ± 15.4units, p = 0.002). Of those asked, 141/143 (98.6 %) stated Omnipod DASH had a positive impact on quality of life.

Conclusions
Omnipod DASH was associated with improvements in HbA1c in PwT1D “new-to-pump” and maintained previous HbA1c levels in those “established-on-pump”. User satisfaction in all groups and TDD reduction in those “new-to-pump” were reported.

Citation

Liarakos, A. L., Hasan, N., Crabtree, T. S. J., Leelarathna, L., Hammond, P., Hussain, S., …Wilmot, E. G. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice, 209, Article 111597. https://doi.org/10.1016/j.diabres.2024.111597

• Journal Article Type: Article
• Acceptance Date: Feb 24, 2024
• Online Publication Date: Feb 27, 2024
• Publication Date: 2024-03
• Deposit Date: Mar 4, 2024
• Publicly Available Date: Mar 4, 2024
• Journal: Diabetes Research and Clinical Practice
• Print ISSN: 0168-8227
• Electronic ISSN: 1872-8227
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 209
• Article Number: 111597
• DOI: https://doi.org/10.1016/j.diabres.2024.111597
• Keywords: Continuous subcutaneous insulin infusion; Omnipod DASH; Tubeless insulin pump; Type 1 diabetes mellitus; Diabetes technology
• Public URL: https://nottingham-repository.worktribe.com/output/32162174
• Publisher URL: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00081-0/fulltext